The field of regenerative medicine is making significant strides, particularly with the development of bioengineered skin ...

Researchers have found a new way to achieve muscle regeneration with a combination of direct cell reprogramming and a hybrid fibre scaffold. While a lot of the body’s muscular tissue can regenerate ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

Researchers have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that can perform complex tasks and self-regulate their composition in ...

When biomedical researchers need to test their latest ideas, they often turn to engineered human tissue that mimics the ...

FDA approves Humacyte's Symvess for urgent vascular repair in extremity arterial injuries when autologous grafts aren't feasible. Symvess provides off-the-shelf bioengineered vascular conduits, ...

Imagine a world where life-saving vaccines could be grown in a garden and consumed in a salad. That’s the potential offered by bioengineered plants capable of producing edible vaccines. This ...

Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...